Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huaier Granules After Non-curative ESD for Early Gastrointestinal Cancer
ChiCTR2600122186Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of huaier granule in gastric cancer (GC), colorectal cancer (CRC) and gastrointestinal cancer (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: 3-year Recurrence-Free Survival (RFS). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
huaier granule
03
Conditions
gastric cancer (GC)colorectal cancer (CRC)gastrointestinal cancer
Beyond the preview
Go deeper on ChiCTR2600122186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122186.